• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Peptides
You are here: Product Lines > Peptides
Toolbar - View Selection
 
 Items 120-140 of 193 Page 7 of 10 Select Page: << 1 2 3 4 5 6 7 8 9 10  >>  
ALX-168-009F Revised 28-Jul-08 New product
L-TAT Control Peptide (for Prod. No. ALX-159-600) (FITC)
Add to Clipboard
SYNONYMS JNK Inhibitor 1 (L-stereoisomer) Control Peptide (for Prod. No. ALX-159-600) (FITC)
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY JNK [SAPK1] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-168-009F-R050 FITC 50 µl 110.00 USD Add To Cart
Product Specification
SEQUENCE: FITC-β-A-RKKRRQRRRA-amide
FORMULA: C80H128N34O17S
MW: 1870.2
CONCENTRATION: 1mM
PURITY: ≥90% (HPLC)
FORMULATION: Liquid. In sterile PBS.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. Keep on ice at all times.
Product Description
Control peptide for L-JNKI. For more details see L-JNKI1 (Prod.No. ALX-159-600).
Product Specific Literature References
Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death: C. Bonny, et al.; Diabetes 50, 77 (2001) Abstract; Full Text
Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation: R. Reinehr, et al.; FASEB J. 17, 731 (2003) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-162-034 Revised 03-Jul-08 New product
MALP-2 (BULK)
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-034-C500   500 µg 1'250.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
CONCENTRATION: 1mg/ml
PURITY DETAIL: HPLC purified
FORMULATION: Liquid. Pyrogen-free, sterile solution in 33% (v/v) 2-propanol/water.
BIOLOGICAL ACTIVITY: Stimulates macrophages, monocytes and other TLR2 and TLR6 expressing cells in vitro at pg/ml concentrations (e.g. mouse macrophages: 50pg/ml; fibroblasts: 2ng/ml) to release various mediators. Human monocytes require about 10-100x higher concentrations for optimal cytokine or chemokine release than mouse PECS (see [12]). In vivo active at 0.5-5μg (e.g 0.5μg/20g mouse). The presence of 50mM octyl glucoside as carrier gives rise to a higher activity.
SHIPPING: SHIPPED ON DRY ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 3 years when stored at -20°C. This stock solution is stable for many months when kept in the refrigerator. MALP-2 solutions in the presene of carrier (50mM octyl glucoside, see Background/Technical Information below) are stable at +4°C at least 6 weeks. Some (10%) decrease of activity may occur shortly after transfer into new vessels. This is not due to decomposition but to adsorption (see below). Storage at room temperature for short periods of time does not influence bioactivity. When deep-frozen, MALP-2 does not loose activity within years.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
New BULK size (500μg) of biologically active, pyrogen-free and sterile MALP-2 for in vitro and animal in vivo studies.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-162-027 Revised 30-Jun-08
MALP-2
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-027-C050   50 µg 310.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
QUANTITY: 1x107units.
CONCENTRATION: 0.1mg/ml
FORMULATION: Liquid. Sterile solution in PBS containing 2.5% (v/v) 2-propanol, 25mM n-octyl-β-D-glucopyranoside and 1% (wt/v) human serum albumin.
ACTIVITY: Specific activity is ~2x108units/mg. One unit is defined as the dilution giving half maximal release of nitric oxide from C3H/HeJ mouse peritoneal exudate cells in the standard assay (see [1]).
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 2 years when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-162-004 Revised 05-Feb-05
MARCKS Protein (151-175) (bovine brain)
Add to Clipboard
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY PKC Substrates
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-004-MC05   0.5 mg 120.00 USD Add To Cart
ALX-162-004-M001   1 mg 210.00 USD Add To Cart
Product Specification
SEQUENCE: H-Lys-Lys-Lys-Lys-Lys-Arg-Phe-Ser-Phe-Lys-Lys-Ser-Phe-Lys-Leu-Ser-Gly-Phe-Ser-Phe-Lys-Lys-Asn-Lys-Lys-OH
FORMULA: C147H243N41O31
MW: 3081.8
CAS NUMBER: 125267-21-2
PURITY: ≥98%
APPEARANCE: White lyophilized powder.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
Product Description
Excellent substrate for protein kinase C (PKC). The peptide consists of residues 151-175 of the myristoylated alanine-rich C-kinase substrate (MARCKS) protein phosphorylation site. Protein kinase C isotypes (including PKCε) phosphorylate serines 8, 12 and 19 of this peptide. It is a very weak substrate for cAMP- and cGMP-dependent protein kinase and CaM kinases I, II and III.
Product Specific Literature References
Protein kinase C substrate and inhibitor characteristics of peptides derived from the myristoylated alanine-rich C kinase substrate (MARCKS) protein phosphorylation site domain: J.M. Graff, et al.; J. Biol. Chem. 266, 14390 (1991) Abstract; Full Text
The MARCKS family of cellular protein kinase C substrates: P.J. Blackshear; J. Biol. Chem. 268, 1501 (1993), (Minireview) Abstract; Full Text
Further Categories Containing This Product:
Peptides
 
 
ALX-162-005 Revised 04-Jul-03
MARCKS Protein (159-165) amide (bovine brain)
Add to Clipboard
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY PKC Substrates
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-005-M001   1 mg 105.00 USD Add To Cart
ALX-162-005-M005   5 mg 420.00 USD Add To Cart
Product Specification
SEQUENCE: H-Phe-Lys-Lys-Ser-Phe-Lys-Leu-NH2
FORMULA: C45H73N11O8
MW: 896.1
PURITY: ≥98%
APPEARANCE: White lyophilized powder.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
Product Description
The peptide consists of residues 159-165 of the myristoylated alanine-rich C-kinase substrate (MARCKS) protein. It is sufficiently selective for protein kinase C (PKC) to permit specific assay of this enzyme in crude cell extracts and permeabilized cells.
Product Specific Literature References
The MARCKS family of cellular protein kinase C substrates: P.J. Blackshear; J. Biol. Chem. 268, 1501 (1993) Abstract; Full Text
: T. Spencker, et al.; Liebigs Ann. Chem. 237, (1993)
Further Categories Containing This Product:
Peptides
 
 
ALX-162-001 Revised 22-Oct-08
Mastoparan
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Neurotoxins
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-001-M001   1 mg 50.00 USD Add To Cart
ALX-162-001-M005   5 mg 200.00 USD Add To Cart
Product Specification
SEQUENCE: H-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
FORMULA: C70H131N19O15
MW: 1478.9
CAS NUMBER: 72093-21-1
SOURCE/HOST: Synthetic. Originally isolated from wasp venom.
PURITY: ≥98%
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in water (1 mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
Product Description

Mast cell degranulating peptide. Stimulates glycogenolysis. Stimulates phospholipase D2 (PLD2) activity. Alters G-proteins in brain membranes.
Product Specific Literature References
A new mast cell degranulating peptide "mastoparan" in the venom of Vespula lewisii: Y. Hirai, et al.; Chem. Pharm. Bull. 27, 1942 (1979) Abstract
Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins): T. Higashijima, et al.; J. Biol. Chem. 263, 6491 (1988) Abstract; Full Text
Mastoparan, a peptide toxin from wasp venom, stimulates glycogenolysis mediated by an increase of the cytosolic free Ca2+ concentration but not by an increase of cAMP in rat hepatocytes: M. Tohkin, et al.; FEBS Lett. 260, 179 (1990) Abstract
Interaction of wasp venom mastoparan with biomembranes: T. Katsu, et al.; Biochim. Biophys. Acta 1027, 185 (1990) Abstract
Effects of the wasp venom peptide, mastoparan, on GTP hydrolysis in rat brain membranes: Y. Odagaki, et al.; Br. J. Pharmacol. 121, 1406 (1997) Abstract
Mastoparan selectively activates phospholipase D2 in cell membranes: A. Chahdi, et al.; J. Biol. Chem. 278, 12039 (2003) Abstract
Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages: A. Lentschat, et al.; J. Immunol. 174, 4252 (2005) Abstract
Biological applications of the receptor mimetic peptide mastoparan: S. Jones & J. Howl; Curr. Protein Pept. Sci. 7, 501 (2006), Review Abstract
Further Categories Containing This Product:
G-proteins & GTPases Other Products • Peptides
 
 
ALX-162-002 Revised 09-Oct-08
MCD Peptide
Add to Clipboard
SYNONYMS Mast Cell Degranulating Peptide
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Neurotoxins
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-002-MC05   0.5 mg 360.00 USD Add To Cart
Product Specification
SEQUENCE: H-Ile-Lys-Cys-Asn-Cys-Lys-Arg-His-Val-Ile-Lys-Pro-His-Ile-Cys-Arg-Lys-Ile-Cys-Gly-Lys-Asn-NH2
(Disulfide bonds between Cys3-Cys15 and Cys5-Cys19)
FORMULA: C110H192N40O24S4
MW: 2587.2
CAS NUMBER: 83856-13-7
SOURCE/HOST: Synthetic. Originally isolated from Apis mellifera.
PURITY: ≥98%
APPEARANCE: Lyophilized.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
Product Description
Potent anti-inflammatory agent and strong mediator of mast cell degranulation and histamine release. Neurotoxin and voltage-dependent K+ channel blocker. Inhibits the ADP-ribosylation of the small GTP-binding proteins rho.
Product Specific Literature References
Bee and wasp venoms: E. Haberman; Science 177, 314 (1972) Abstract
Potassium channel toxins: P.N. Strong; Pharmacol. Ther. 46, 137 (1990) Abstract
Mast cell degranulating peptide: a multi-functional neurotoxin: M.R. Ziai, et al.; J. Pharm. Pharmacol. 42, 457 (1990), Review Abstract
ADP-ribosylation of rho proteins is inhibited by melittin, mast cell degranulating peptide and compound 48/80: G. Koch, et al.; Eur. J. Pharmacol. 226, 87 (1992) Abstract
Further Categories Containing This Product:
Peptides • K+ Channel Blockers & Inhibitors • Natural Products - Anti-inflammatory Agents
 
 
ALX-162-006 Revised 07-Apr-08
Melittin (natural)
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Protein Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-006-M001   1 mg 40.00 USD Add To Cart
ALX-162-006-M005   5 mg 160.00 USD Add To Cart
Product Specification
SEQUENCE: H-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2
FORMULA: C131H229N39O31
MW: 2846.5
CAS NUMBER: 37231-28-0
MERCK INDEX: 14: 5824
RTECS: OS3960000
SOURCE/HOST: Isolated from bee venom.
PURITY: ≥85% (HPLC)
APPEARANCE: Off-white to faint tan powder.
PURITY DETAIL: Phospholipase A2 impurity: <5 units per mg solid.
SOLUBILITY: Soluble in PBS (5mg/ml) or water (5mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Very hygroscopic. Protect from light.
HAZARD: HARMFUL.
Product Description
Causes disruption of normal cellular activity and cell lysis. Binds calmodulin in a calcium-dependent manner. Activates phospholipase A2 (PLA2) and inhibits protein kinase C (PKC) by binding to the catalytic domain in a Mg-ATP sensitive manner. Antirheumatic.
Product Specific Literature References
Rapid purification of calmodulin and S-100 protein by affinity chromatography with melittin immobilized to sepharose: R.L. Kincaid & C.C. Coulson; BBRC 133, 256 (1985) Abstract
Comparison of S100b protein with calmodulin: interactions with melittin and microtubule-associated tau proteins and inhibition of phosphorylation of tau proteins by protein kinase C: J. Baudier, et al.; Biochemistry 26, 2886 (1987) Abstract
Possible mechanisms of action of cobra snake venom cardiotoxins and bee venom melittin: J.E. Fletcher & M.S. Jiang; Toxicon. 31, 669 (1993) Abstract
Melittin and phospholipase A2 from bee (Apis mellifera) venom cause necrosis of murine skeletal muscle in vivo: C.L. Ownby, et al.; Toxicon. 35, 67 (1997) Abstract
Melittin binds to secretory phospholipase A2 and inhibits its enzymatic activity: S.S. Saini, et al.; BBRC 238, 436 (1997) Abstract
Phospholipase A2-independent Ca2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells: S.T. Chu, et al.; Life Sci. 80, 364 (2007) Abstract
Further Categories Containing This Product:
Calmodulin Other Products • PKC Inhibitors • Peptides • PLA2 Activators
 
 
ALX-162-007 Revised 12-May-05